(a) Authorized Organizational Official. The individual, named by the applicant organization, who is authorized to act for the applicant organization and to assume the obligations imposed by the laws, regulations, requirements, and conditions that apply to applications and awards.

(b) Budget Period. The intervals of time (usually 12 months) into which a Project Period is divided for budgetary funding and reporting purposes as specified in the relevant NGA.

(c) CIRM-Funded Invention. An Invention, whether patentable or not, which arises from CIRM-Funded Research and is either:

(d) CIRM-Funded Project or Activity. Those activities specified or described in an Application that are approved by the ICOC for funding and for which CIRM has issued an NGA, regardless of whether CIRM funding constitutes all or only a portion of the financial support necessary to carry them out.

(e) CIRM-Funded Research. All aspects of work conducted on a CIRM-Funded Project or Activity that is paid for, in whole or in part, with CIRM funds.

(f) CIRM-Funded Technology. Data, materials, research results or know-how whether patentable or not, that is generated or conceived in the Project Period of a Grant and is paid for in whole or in part with CIRM-funds.

(g) Collaborator. Any person or entity other than a Grantee and Grantee Personnel who (1) receives directly or indirectly CIRM funding for work performed under a Grant, and (2) who obtains any ownership rights to a CIRM-Funded Invention or CIRM-Funded Technology during the Project Period.

(h) Commercializing Entity. A For-Profit Grantee and its Collaborator or licensee that sells, offers for sale or transfers a Drug product(s) or service(s) resulting in whole or in part from CIRM-Funded Research.

(i) Data. Scientific, clinical or technical recorded information derived during the Project Period of a Grant, regardless of form or the media on which it may be recorded, but not any of the following: financial, administrative, management data, other information incidental to contract administration, preliminary analyses, drafts of scientific papers, plans for future research, peer reviews, or communications with colleagues. “Data” excludes physical objects (e.g., laboratory samples).

(j) Drug. (1) An article recognized in the official United States Pharmacopoeia, Homoeopathic Pharmacopoeia of the United States, or National Formulary, or any supplement to any of them; (2) an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or animals; or, (3) an article intended for use as a component of any article specified in subdivision (1) or (2). This term includes therapeutic products such as blood, blood products and cells, but excludes medical procedures and services relating thereto.

(k) Exclusive License. A License Agreement that conveys to an individual or entity the sole right to make, use, sell, offer for sale and/or import a CIRM-Funded Invention or CIRM-Funded Technology in any field of use or territory, or an agreement that precludes conveyance of the right to make, use, sell, offer for sale and/or import, in any field of use or territory, a CIRM-Funded Invention or CIRM-Funded Technology to another.

(l) Exclusive Licensee. Any individual or entity receiving the sole right to make, use, sell, offer for sale and/or import a CIRM-Funded Technology or a CIRM-Funded Invention in any field of use or territory.

(m) First Commercial Sale. The date upon which revenue is derived from the sale or transfer, but not the licensing or assignment, of a Drug, product or service in the United States or member country of the European Union.

(n) For-Profit Organization. A sole-proprietorship, partnership, limited liability company, corporation, or other legal entity that is organized or operated for the profit or financial benefit of its shareholders or other owners.

(o) Grant. A funding mechanism, other than a loan, providing money and/or property to an eligible entity to assist the recipient in carrying out all or any portion of a CIRM-Funded Project or Activity.

(p) Grantee. The Non-Profit Organization or For-Profit Organization awarded a Grant by CIRM that is legally responsible and accountable for the use of the CIRM funds provided for the performance of the grant-supported project or activity. The Grantee is the entire legal entity, including Affiliates, even if only a particular division is designated in the Notice of Grant Award (“NGA”). An entity is an Affiliate of a Grantee if both entities share substantial common direction or control (either directly or indirectly), or if either entity owns (directly or through one or more entities) at least a 25% capital or profits interest in the other. All University of California Grantee campuses shall be considered as separate and individual Grantees.

(q) Grantee Personnel. Grantee's Principal Investigator(s) and Grantee's employees, students and contractors working under the direct or indirect supervision of the Principal Investigator or a Co-Principal Investigator under the Grant.

(r) Invention. A discovery that is conceived and/or reduced to practice, whether patentable or not.

(s) Inventor. A person who is an inventor under the patent law of the relevant governing jurisdiction.

(t) License Agreement. An agreement by which the holder of rights in a CIRM-Funded Invention or CIRM-Funded Technology conveys to another individual or entity the right to make, use, develop, sell, offer to sell, and/or import a CIRM-Funded Invention or CIRM-Funded Technology or which precludes the holder of such rights from enforcing those rights against such other individual or entity.

(u) Licensing Activities. Efforts of an owner or Collaborator of a CIRM-Funded Invention or CIRM-Funded Technology to negotiate, execute or enforce a License Agreement.

(v) Licensing Revenue. The consideration received for the grant of rights (including license rights), or an agreement to not enforce rights, to make, use, develop, sell, offer to sell, and/or import a CIRM-Funded Invention or CIRM-Funded Technology, excluding the following: (1) any additional grants, loans and other forms of research funding obtained to support the Project; (2) consideration received prior to commercialization of the CIRM-Funded Invention or CIRM-Funded Technology, such as development milestones and upfront payments, by For-Profit Grantees and/or For-Profit Collaborators who have expended, or are expending, their own funds on developing the CIRM-Funded Invention or CIRM-Funded Technology; and (3) consideration derived from Net Commercial Revenue upon which CIRM has received payment from a Commercializing Entity pursuant to section 100608(b).

Calculation: Revenue is calculated by subtracting a proportion of expenses reasonably incurred in prosecuting, defending and enforcing related patent rights equal to CIRM's percentage of support for development of such CIRM-Funded Invention and/or CIRM-Funded Technology from total consideration rendered, except to the extent that such expenses are recoverable from a third party as provided in section 100605(c), or otherwise. In the case of nonprofit Grantees and non-profit Collaborators, Licensing Revenue is calculated by subtracting amounts due to the Inventor pursuant to existing non-profit Grantees' or non-profit Collaborators' policies from total consideration rendered, in addition to the deduction of expenses per the previous sentence.

(w) Material Transfer Agreement (“MTA”). An agreement that governs the transfer of tangible research material between a Grantee and/or its Collaborator and an individual or entity (“Recipient”) and defines the rights of the Grantee and the rights and limitations of the Recipient with respect to the materials and any derivatives therefrom.

(x) Net Commercial Revenue. Gross amounts invoiced for the sale in any country or transfer (but not licensing or assignment) of a Drug, or product(s) or service(s) resulting in whole or in part from CIRM-Funded Research. Net Commercial Revenue excludes the following (as they pertain to the making, using or selling of products resulting from CIRM-Funded Research):

(y) Non-Exclusive License. A License Agreement under which the rights transferred or conveyed in a CIRM-Funded Technology or a CIRM-Funded Invention to the licensee remain available to be licensed to one or more entities.

(z) Non-Exclusive Licensee. Any individual or entity that obtains the right to make, use, sell, offer for sale and/or import in a specific field of use or territory, CIRM-Funded Technology or a CIRM-Funded Invention, through a Non-Exclusive License.

(aa) Non-Profit Organization. A university or other institution of higher education or another organization of the type described in 501(c)(3) of the Internal Revenue Code of 1986, as amended (26 U.S.C. 501 (c)(3)) and is exempt from taxation under 501 (a) of the Internal Revenue Code (26 U.S.C. 501 (a)) and California Revenue and Taxation Code section 23701d.

(bb) Notice of Grant Award (“NGA”). The document that notifies the Grantee and others that an award has been made, contains or references all terms and conditions of the award as well as the Grantee's and Principal Investigator's agreement to those terms and conditions, and documents the commitment of CIRM funds.

(cc) Principal Investigator. The Principal Investigator (“PI”) is an individual designated by the Grantee to direct CIRM-Funded Research. He or she is responsible and accountable to the Grantee and CIRM for the proper conduct of the project or activity. References herein to “Principal Investigator” include Co-Principal Investigators as well.

(dd) Project Period. The amount of time over which CIRM funds a specific Grant.

(ee) Public Funds. Funds belonging to the State of California or of any county, city, city and county, or other municipal corporation or subdivision thereof, or any public agency therein.

(ff) Publication-Related Biomedical Materials. Tangible research material of biomedical relevance first produced in the course of CIRM-Funded Research including but not limited to unique research resources (such as synthetic compounds, organisms, cell lines, viruses, cell products, cloned DNA, as well as DNA sequences, mapping information, crystallographic coordinates, and spectroscopic data), as described in a published scientific paper as provided by Title 17, California Code of Regulations, section 100603. Specific examples include specialized and/or genetically defined cells, including normal and diseased human cells, monoclonal antibodies, hybridoma cell lines, microbial cells and products, viruses and viral products, recombinant nucleic acid molecules, DNA probes, nucleic acid and protein sequences, certain types of animals including transgenic mice and other property such as computer programs. This term does not include tangible research material of biomedical relevance that is made commercially available by a Grantee, Grantee Personnel, Licensee or a Collaborator, as determined by CIRM pursuant to Title 17, California Code of Regulations section 100604, subdivision (e).